New Product Announcements

New Areas of Relief Ahead

With more than 70 published, peer reviewed, controlled trials, Visbiome® remains one of the most widely studied probiotics available on the market.

Our 8-strain, high-potency probiotic medical food has proven beneficial in the physician-guided, dietary management of digestive issues related to:  

  • Irritable Bowel Syndrome (IBS)
  • Ulcerative Colitis (UC)
  • Pouchitis
  • Hepatic Encephalopathy (HE)

New Areas of Relief Ahead

With more than 70 published, peer reviewed, controlled trials, Visbiome® remains one of the most widely studied probiotics available on the market.

Our 8-strain, high-potency probiotic medical food has proven beneficial in the physician-guided, dietary management of digestive issues related to:  

  • Irritable Bowel Syndrome (IBS)
  • Ulcerative Colitis (UC)
  • Pouchitis
  • Hepatic Encephalopathy (HE)

But why stop there?

Our team is hard at work on new product development and is dedicated to expanding the use of Visbiome in a variety of therapeutic areas.

In fact, Visbiome is the focus of upcoming clinical studies in a number of areas, including:

  • Colic in infants
  • Multiple Sclerosis
  • Newly diagnosed Type 1 diabetes
  • HIV
  • Autism Spectrum Disorder
  • Cirrhosis plus Spontaneous Bacterial Peritonitis
  • Pre-Diabetic Adolescents
  • Eradication of Extended Spectrum BetaLactam (ESBL) colonization in adult
  • Portal Hypertension
  • Severe Depression
  • And more

Be the First to Know

We want to keep you in the loop. Fill out the form below to sign up for email alerts about exciting new product announcements from Visbiome.

Please Note

You are now leaving Visbiome.com (USA) for Visbiome Canada.

Proceed to Visbiome Canada Stay on the US site